JIVI 500 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION

Introduction

Package Leaflet: Information for theuser

Jivi 250 UI powder and solvent for solutionfor injection

Jivi 500 UI powder and solvent for solutionfor injection

Jivi 1000 UI powder and solvent for solutionfor injection

Jivi 2000 UI powder and solvent for solutionfor injection

Jivi 3000 UI powder and solvent for solutionfor injection

human recombinant coagulation factor VIII pegylated with B domain suppressed (damoctocog alfa pegol)

Read all of this leaflet carefully before you start using this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.

• If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the package leaflet

1. What is Jivi and what is it used for
2. What you need to know before you start using Jivi
3. How to use Jivi
4. Possible side effects
5. Storage of Jivi
6. Contents of the pack and further information

1. What is Jivi and what is it used for

Jivi contains the active substance damoctocog alfa pegol. It is produced using recombinant technology without the addition of any human or animal-derived components in the manufacturing process. Factor VIII is a protein that occurs naturally in the blood and helps it to clot. The damoctocog alfa pegol protein has been modified (pegylated) to prolong its action in the body.

Jivi is used to treat and prevent bleedingin adults and adolescents aged 12 years or older with haemophilia A (hereditary factor VIII deficiency) who have been previously treated. It is not for use in children under 12 years.

2. What you need to know before you start using Jivi

Do not use Jivi if you are:

• allergic to damoctocog alfa pegol or any of the other ingredients of this medicine (listed in section 6).
• allergic to mouse or hamster proteins.

Warnings and precautions

Talk to your doctor or pharmacist if:

? you experience chest tightness, a drop in blood pressure (often manifested by a feeling of dizziness when standing up quickly), urticaria with itching, wheezing (whistling when breathing), general malaise or fainting. These may be signs of a severe allergic reactionto this medicine. Stopthe injection of the medicineimmediately and seek medical attention if this occurs.

• you have a bleed that does not stop with your usual dose of this medicine. Talk to your doctor immediately if this happens. You may have developed antibodies against factor VIII (inhibitors) or antibodies against polyethylene glycol (PEG). These antibodies reduce the effectiveness of Jivi in preventing and controlling bleeding. Your doctor may perform tests to confirm this possibility and ensure that your dose of Jivi generates adequate levels of factor VIII. If necessary, your doctor may switch you back to your previous factor VIII treatment.
• you have previously developed factor VIII inhibitors with a different product.
• you have a history of heart disease or are at risk of heart disease.
• you need to use a central venous access device for this medicine. You may be at risk of complications related to the device in the area where the catheter is inserted, including:

• local infections
• bacteria in the blood
• formation of a blood clot in the blood vessel

Children

Jivi must not be used in children under 12 years.

Other medicines and Jivi

It is not known whether Jivi affects or is affected by other medicines. Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

Driving and using machines

Jivi has no influence on the ability to drive and use machines.

Jivi contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per dose; i.e. it is essentially “sodium-free”.

3. How to use Jivi

Treatment with Jivi will be started by a doctor who is experienced in the care of patients with haemophilia A. After receiving appropriate training, patients or carers may be able to administer Jivi at home. Follow the instructions for administration of this medicine exactly as told by your doctor. If you are unsure, consult your doctor or pharmacist again. The dose of factor VIII is measured in International Units (IU).

Treatment of bleeding

To treat bleeding, your doctor will calculate and adjust your dose and how often it should be administered, depending on factors such as:

• your weight

• the severity of your haemophilia A
• the location and severity of the bleeding
• whether you have factor VIII inhibitors and how high these levels are
• the required level of factor VIII

Prevention of bleeding

To prevent bleeding, your doctor will select a dose and frequency based on your needs:

• 45-60 IU per kg body weight every 5 days or
• 60 IU per kg body weight every 7 days or
• 30-40 IU per kg body weight twice a week.

Lab tests

Regular lab tests help to ensure that you always have adequate levels of factor VIII. In the case of major surgery, your blood clotting should be closely monitored.

Duration of treatment

Generally, treatment for haemophilia with Jivi will be needed for life.

How Jivi is administered

Jivi is injected into a vein over 2-5 minutes, depending on the total volume and your comfort level. The maximum speed is 2.5 ml per minute. Jivi must be used within 3 hours after reconstitution.

How to prepare Jivi for injection

Only use the components (vial adapter, pre-filled syringe with solvent and venipuncture equipment) included in the package for this medicine. Consult your doctor if it is not possible to use these components. If any of the components of the package are open or damaged, do not use this component.

The reconstituted medicine must be filtered using the vial adapterbefore injection to remove any particles that may be present in the solution.

This medicine must notbe mixed with other injections. Do not use solutions that are cloudy or contain visible particles. Follow the instructions for usegiven by your doctor and those at the end of this leaflet.

If you use more Jivi than you should

Tell your doctor if this happens. No symptoms of overdose have been reported.

If you forget to use Jivi

Inject the next dose as soon as possible and continue at regular intervals, following the instructions of your doctor.

Do not use a double dose to make up for forgotten doses.

If you stop using Jivi

Do not stop using this medicine without talking to your doctor.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The most seriousside effects are allergic reactionsor a severe allergic reaction. Stop the injection of Jivi immediately and talk to your doctor right away if this happens.The following symptoms could be an early sign of these reactions:

• chest tightness or general feeling of discomfort
• burning and itching at the injection site
• urticaria, flushing
• drop in blood pressure that can cause dizziness when standing up
• nausea

In patients who have received previous treatment with factor VIII (more than 150 days of treatment), inhibitor antibodies (see section 2) may rarely form (less than 1 in 100 patients). If this happens, your medicine may stop working well and you may experience persistent bleeding. If this happens, contact your doctor immediately.

The following side effects may occur with this medicine:

Very common(may affect more than 1 in 10 people):

• headache

Common(may affect up to 1 in 10 people):

• stomach pain
• nausea, vomiting
• fever
• allergic reactions (which can occur in the form of hives, generalised urticaria, chest tightness, wheezing, shortness of breath, drop in blood pressure; for initial symptoms, see above)

? local reactions at the injection site, such as bleeding under the skin, severe itching, swelling, burning sensation, transient redness

• dizziness
• difficulty sleeping
• cough
• rash, skin redness

Uncommon(may affect up to 1 in 100 people):

• factor VIII inhibition
• taste disturbance
• flushing
• itching

Reporting of side effects

If you experience any side effects, talk to your doctor, even if they are not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Agency’s online platform at www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Jivi

Keep this medicine out of the sight and reach of children.

Do notuse this medicine after the expiry date which is stated on the labels and cartons. The expiry date is the last day of the month stated.

Store in a refrigerator (between 2°C and 8°C). Do notfreeze.

Keep the vial and pre-filled syringe in the outer packaging to protect from light.

This medicine can be stored at room temperature (below 25°C) for a maximum of 6 months if kept in the package. If stored at room temperature, the expiry date is either 6 months or the expiry date stated, whichever is earlier.

You must write the new expiry date on the outer packaging when you remove the medicine from the refrigerator.

Do notrefrigerate the solution after reconstitution. The reconstituted solution must be used within 3 hours.

Do notuse this medicine if you notice particles or if the solution is cloudy.

This medicine is for single use only. Discard any unused solution.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist or doctor how to dispose of the packaging and any unused medicines. This will help protect the environment.

6. Package Contents and Additional Information

Jivi Composition

• The active substance is human recombinant coagulation factor VIII pegylated with B domain suppressed (damoctocog alfa pegol). Each vial of Jivi contains 250 or 500 or 1000 or 2000 or 3000 IU of damoctocog alfa pegol. After reconstitution with the supplied solvent (sterile water for injections), the prepared solutions have the following concentration:

• The other components are sucrose, histidine, glycine, sodium chloride (see section 2 "Jivi contains sodium"), calcium chloride dihydrate, polysorbate 80, glacial acetic acid, and water for injections.

Appearance and Package Contents of the Product

Jivi is presented as a powder and solvent for solution for injection. The powder is dry and white to slightly yellow. The solvent is a clear liquid. After reconstitution, the solution is clear.

Each package of Jivi contains

• a glass vial with powder
• a pre-filled syringe with solvent
• a separate plunger rod
• a vial adapter
• a venipuncture set

Jivi is available in packages of:

• 1 individual package
• 1 multiple package with 30 individual packages

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Bayer AG

51368 Leverkusen

Germany

Manufacturer

Bayer AG

Kaiser-Wilhelm-Allee

51368 Leverkusen

Germany

You can request more information about this medicinal product from the local representative of the marketing authorisation holder:

Date of Last Revision of this Leaflet:

Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu

------------------------------------------------------------------------------------------------------------------

Detailed Instructions for Reconstitution and Administration of Jivi

You will need sterile alcohol-impregnated swabs, sterile swabs, dressings, and a tourniquet. These items are not included in the Jivi package.